Aurelie Martin, Presenter: Nothing to Disclose

Clarisse Dromain MD, Abstract Co-Author: Nothing to Disclose

Valérie Boige MD, Abstract Co-Author: Nothing to Disclose

François Bidault MD, Abstract Co-Author: Nothing to Disclose

Michel Ducreux, Abstract Co-Author: Nothing to Disclose

Robert C. Sigal MD, PhD, Abstract Co-Author: Nothing to Disclose

To correlate liver dynamic perfusion CT with usual tumor response criteria (RECIST) in hepatocellular carcinoma (HCC) treated by antiangiogenesis inhibitor.

Fourteen patients with HCC treated by Bevacizumab were prospectively evaluated, using CT perfusion measurement. Five CT parameters were assessed: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability surface (PS) and hepatic arterial fraction (HAF). Patients were classified into two groups: responders and non responders, according to RECIST criteria and survival. Forty one examinations were performed: 14 at baseline, 14 at 4 cycles, 9 at 8 cycles, 2 at 12 cycles, 1 at 16 cycles and 1 at 20 cycles.

BV and HAF were evaluated between baseline and last cycle: mean BV values increased of 96% in responders and decreased of 26% in non responders, mean HAF values decreased of 47% in responders and increased of 1% in non responders. A combination of a decrease of HAF and an increase of BV was strongly correlated with tumor response (p<10-4).

Dynamic perfusion CT is a new imaging technique which might be an effective tool to evaluate antiangiogenic drugs in HCC.

Matching functional CT parameters with usual tumor response criteria in order to improve early assessment of tumor response to antiangiogenesis treatment.

Martin, A, Dromain, C, Boige, V, Bidault, F, Ducreux, M, Sigal, R, CT Perfusion in the Evaluation of Response of Hepatocellular Carcinoma under Bevacizumab.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5005035.html